“…In LCH, BRAF V600E is the most frequently detected mutation, followed by MAP2K1 alterations [1,2,5,7,8]. The occurrence of mutations seems to cause a more severe course and resistance to conventional chemotherapy, with potentially higher mortality and severe secondary conditions such as neurodegenerative disease (ND) or sclerosing cholangitis (SC) with consequent liver cirrhosis [7,[9][10][11][12].…”